PMID- 25913922 OWN - NLM STAT- MEDLINE DCOM- 20160406 LR - 20220331 IS - 1879-114X (Electronic) IS - 0149-2918 (Linking) VI - 37 IP - 7 DP - 2015 Jul 1 TI - Effects of Febuxostat on Oxidative Stress. PG - 1396-401 LID - S0149-2918(15)00186-1 [pii] LID - 10.1016/j.clinthera.2015.03.026 [doi] AB - PURPOSE: We previously examined factors that affect the measured derivatives of reactive oxygen metabolites (d-ROMs), an indicator of reactive oxygen species production, and biological antioxidant potential (BAP), an indicator of antioxidant capacity, in typical health checkup examinees and reported the usefulness of measuring both indicators simultaneously. In addition, a positive correlation reportedly exists between d-ROMs and the visceral fat area measured by using computed tomography. A recent study of the relationship between uric acid levels and various obesity-related factors found that visceral fat was the factor most strongly related to uric acid levels. Uric acid is itself a potent endogenous antioxidant, but because reactive oxygen species are produced during uric acid generation, it is suggested that uric acid may have opposing effects. The objective of this study was to analyze the effect of febuxostat, a novel xanthine oxidase inhibitor, on oxidative stress. METHODS: Study subjects were 43 hyperuricemia outpatients receiving care in the internal medicine department of our institution. The subjects were divided into a new administration group (29 patients) and a switched administration group (14 patients); the latter were allopurinol-treated patients with hyperuricemia who were switched to febuxostat. In addition to measuring the patients' uric acid and creatinine levels and estimated glomerular filtration rate before and after treatment, their d-ROMs and BAP as well as the BAP/d-ROMs ratio were also measured. FINDINGS: Both groups exhibited significant decreases in uric acid levels, as well as significant decreases in d-ROMs and BAP. No significant changes were observed in the BAP/dROMs ratio or renal function, including creatinine levels and estimated glomerular filtration rate. IMPLICATIONS: Febuxostat could significantly reduce d-ROMs. However, BAP levels were also significantly reduced concurrently. No changes were observed in the BAP/d-ROMs ratios. This regulatory mechanism is believed to have counteracted changes in the in vivo oxidative stress balance caused by febuxostat administration. CI - Copyright (c) 2015 Elsevier HS Journals, Inc. All rights reserved. FAU - Fukui, Toshiki AU - Fukui T AD - Center for Preventive Medical Treatment, NTT West Takamatsu Hospital, Kagawa, Japan. Electronic address: ftoshi@kagawa.west.ntt.co.jp. FAU - Maruyama, Mie AU - Maruyama M AD - Center for Preventive Medical Treatment, NTT West Takamatsu Hospital, Kagawa, Japan. FAU - Yamauchi, Kazuhiro AU - Yamauchi K AD - Center for Preventive Medical Treatment, NTT West Takamatsu Hospital, Kagawa, Japan. FAU - Yoshitaka, Sumie AU - Yoshitaka S AD - Center for Preventive Medical Treatment, NTT West Takamatsu Hospital, Kagawa, Japan. FAU - Yasuda, Tadashi AU - Yasuda T AD - Center for Preventive Medical Treatment, NTT West Takamatsu Hospital, Kagawa, Japan. FAU - Abe, Youichi AU - Abe Y AD - Center for Preventive Medical Treatment, NTT West Takamatsu Hospital, Kagawa, Japan. LA - eng PT - Journal Article DEP - 20150423 PL - United States TA - Clin Ther JT - Clinical therapeutics JID - 7706726 RN - 0 (Enzyme Inhibitors) RN - 0 (Gout Suppressants) RN - 0 (Reactive Oxygen Species) RN - 101V0R1N2E (Febuxostat) RN - 268B43MJ25 (Uric Acid) RN - 63CZ7GJN5I (Allopurinol) RN - AYI8EX34EU (Creatinine) SB - IM MH - Adult MH - Aged MH - Allopurinol/therapeutic use MH - Creatinine/blood MH - Enzyme Inhibitors/therapeutic use MH - Febuxostat/*pharmacology/therapeutic use MH - Female MH - Glomerular Filtration Rate/drug effects/physiology MH - Gout Suppressants/*pharmacology/therapeutic use MH - Humans MH - Hyperuricemia/blood/*drug therapy/physiopathology MH - Kidney/physiopathology MH - Male MH - Middle Aged MH - Oxidative Stress/*drug effects MH - Reactive Oxygen Species/*blood MH - Uric Acid/*blood OTO - NOTNLM OT - BAP OT - d-ROMs OT - febuxostat OT - oxidative stress OT - uric acid OT - xanthine oxidase EDAT- 2015/04/29 06:00 MHDA- 2016/04/07 06:00 CRDT- 2015/04/28 06:00 PHST- 2014/11/22 00:00 [received] PHST- 2015/03/04 00:00 [revised] PHST- 2015/03/29 00:00 [accepted] PHST- 2015/04/28 06:00 [entrez] PHST- 2015/04/29 06:00 [pubmed] PHST- 2016/04/07 06:00 [medline] AID - S0149-2918(15)00186-1 [pii] AID - 10.1016/j.clinthera.2015.03.026 [doi] PST - ppublish SO - Clin Ther. 2015 Jul 1;37(7):1396-401. doi: 10.1016/j.clinthera.2015.03.026. Epub 2015 Apr 23.